Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jun 30;5(7):e601.
doi: 10.1097/HS9.0000000000000601. eCollection 2021 Jul.

The EHA Research Roadmap: Platelet Disorders

Carlo Balduini  1 , Kathleen Freson  2 , Andreas Greinacher  3 , Paolo Gresele  4 , Thomas Kühne  5 , Marie Scully  6 , Tamam Bakchoul  7 , Paul Coppo  8 , Tadeja Dovc Drnovsek  9 , Bertrand Godeau  10 , Yves Gruel  11 , A Koneti Rao  12 , Johanna A Kremer Hovinga  13 , Michael Makris  14 , Axel Matzdorff  15 , Andrew Mumford  16 , Alessandro Pecci  17 , Hana Raslova  18 , José Rivera  19 , Irene Roberts  20 , Rüdiger E Scharf  21 , John W Semple  22 , Christel Van Geet  23
Affiliations
Editorial

The EHA Research Roadmap: Platelet Disorders

Carlo Balduini et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Caplacizumab improves prognosis of acquired TTP. This large European study revealed that caplacizumab added to plasma exchange shortens the time for normalization of the platelet count. This translates in a lower incidence of a composite of TTP-related death, recurrence of TTP, a thromboembolic event during the treatment period, and a lower rate of recurrence of TTP. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. TTP = thrombotic thrombocytopenic purpura.
Figure 2.
Figure 2.
Eltrombopag increases platelet count in inherited thrombocytopenias. In this collaborative study, the thrombopoietin-receptor agonist eltrombopag brought the number of platelets to a safe level in patients with 4 different forms of inherited thrombocytopenia. The authors concluded that this drug can be used in place of platelet transfusions to prepare patients for hemostatic challenges. Reprinted with permission from Zaninetti et al. ANKRD26-RT = ANKRD26-related thrombocytopenia; mBSS = monoallelic Bernard-Soulier syndrome; MYH9-RD = MYH9-related disease; XLT/WAS = X-linked thrombocytopenia/Wiskott-Aldrich syndrome.
See this image and copyright information in PMC

References

    1. Engert A, Balduini C, Brand A, et al. . The European Hematology Association Roadmap for European Hematology Research: A consensus document. Haematologica. 2016; 101:115–208 - PMC - PubMed
    1. Scully M, Cataland SR, Peyvandi F, et al. ; HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019; 380:335–346 - PubMed
    1. Zaninetti C, Gresele P, Bertomoro A, et al. . Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial. Haematologica. 2020; 105:820–828 - PMC - PubMed
    1. Lentaigne C, Freson K, Laffan MA, et al. ; BRIDGE-BPD Consortium and the ThromboGenomics Consortium. Inherited platelet disorders: toward DNA-based diagnosis. Blood. 2016; 127:2814–2823 - PMC - PubMed
    1. Megy K, Downes K, Simeoni I, et al. ; Subcommittee on Genomics in Thrombosis and Hemostasis. Curated disease-causing genes for bleeding, thrombotic, and platelet disorders: communication from the SSC of the ISTH. J Thromb Haemost. 2019; 17:1253–1260 - PMC - PubMed

Publication types